Maximize Discovery Insights—at Scale

To scale biomarker discovery projects, researchers often need to transition from manual, single-modality experiments to automated and standardized platform-based systems. Using specific, application-validated recombinant monoclonal antibodies helps ensure you have the lot-to-lot consistency needed for multiplex, multiomics, and higher-throughput workflows. Employing multiplexing and multiomics technologies enables the detection of more biomarkers per sample, thereby maximizing the data obtained from limited, precious biological samples.

Multiplexing is the simultaneous detection and quantification of multiple biological analytes—such as proteins, DNA, or RNA—within a single experimental run or tissue slide. In exploratory research, multiplexing helps scale discovery workflows by enabling researchers to obtain the ‘full picture’ of a cellular environment from limited, precious samples. Multiplexing with an automated system can offer the simultaneous processing of multiple samples, reducing instrument costs, minimizing batch variability, and increasing experimental throughput.

Multiplexing with specific, validated antibodies allows researchers to visualize many biomarkers simultaneously within a single tissue section. A high-plex approach can map complex cellular neighborhoods and rare cell subsets in the tissue microenvironment. By using application-validated solutions for multiplexing, such as specific fluorophore-conjugated antibodies, oligo-conjugated antibodies, or SignalStar^® Multiplex IHC, scientists can save weeks of optimization time and conserve precious FFPE samples while examining the localization and spatial context of proteins and PTMs within cellular architecture.

Multiomics is an approach that integrates multiple layers of molecular data, such as the genome, transcriptome, and proteome, to simultaneously analyze them from a single sample, revealing new insights about cellular processes. In discovery research, multiomics helps bridge the gap between genetic potential (DNA and RNA) and functional activity (proteins and PTMs). Technologies like InTraSeq^™ Single Cell Analysis reveal signaling perturbations and rare cell subtypes that can go unseen in single-modality assays, providing a more comprehensive understanding of the complex molecular mechanisms driving disease.

Recombinant monoclonal antibodies are engineered to offer unparalleled specificity and lot-to-lot consistency, eliminating the variability and genetic drift that commonly occur with traditional polyclonal or hybridoma-produced antibodies. CST recombinant monoclonal antibodies are extensively and rigorously validated in the tissues, species, and applications for which they’re approved. This reliability is the foundation needed for scaling biology experiments and projects, to ensure reproducibility across labs, teams, and high-throughput automated platforms.

CST provides the necessary foundation for next-gen technology by offering a broad portfolio of recombinant monoclonal antibodies that are both sensitive and specific, as well as application-validated, making them highly reliable and compatible with popular spatial biology and multiomics platforms. Our antibody reagents are available in a variety of formats, including BSA- and azide-free formulations, fluorophore-conjugated formats, and custom oligo-conjugated formats, to ensure seamless compatibility with instruments such as 10x Genomics Visium, Akoya PhenoCycler, and Olink assays. By integrating trusted high-quality reagents into next-generation workflows, researchers can scale their projects with confidence and avoid the strain of unreliable data, wasted resources, and repeat work.